共 113 条
- [1] Cowan AJ(2022)Diagnosis and management of multiple myeloma: a review JAMA 327 464-477
- [2] Green DJ(2022)Current approaches to management of newly diagnosed multiple myeloma Am J Hematol 97 S3-S25
- [3] Kwok M(2022)Promising therapeutic approaches for relapsed/refractory multiple myeloma Hematology 27 343-352
- [4] Lee S(2021)Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma Leuk Lymphoma 62 3087-3097
- [5] Coffey DG(2015)Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Blood 125 2068-2074
- [6] Holmberg LA(2019)Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older J Geriatr Oncol 33 648-657
- [7] Goel U(2020)A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Leukemia 34 224-233
- [8] Usmani S(2014)International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 e538-e548
- [9] Kumar S(2006)International uniform response criteria for multiple myeloma Leukemia 20 1467-1473
- [10] Ni B(2022)Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update Am J Hematol 97 99-118